Haorui Pharma-Chem Inc.
About Haorui Products Technology Contact
 
API Index
 
A
Adapalene
Alfuzosin HCl
  Altrenogest 
  Amifostine
  5-Aminolevulinic acid 
  Amisulpride
  Amlexanox
  Amorolfine HCl   
  Anastrozole 
  Ascomycin (FK520)
  Atracurium besylate
  Azelastine HCl
  Aztreonam
  B
  Benidipine HCl 
  Bicalutamide
  Brimonidine tartrate
  C
  Camptothecin
  Candesartan cilexetil 
  Capecitabine
  D
  Daptomycin
  Dasatinib
  Desogestrel
  Dexrazoxane 
  Dirithromycin
  Dipeptiven
  Docetaxel
  Dofetilide
  Dolasetron mesylate
  Donepezil HCl
  Doramectin
  Doxazosin mesylate
  Drospirenone
  E
  Entecavir
  Epalrestat
  Eplerenone
  Epinastine HCl
  Eplerenone
  Erlotinib HCl
  Erythromycin ethylsuccinate
  Escitalopram oxalate
  Estradiol
  Estradiol Benzoate
  Estriol
  Ethinyl Estradiol
  Everolimus
  Exemestane
  Everolimus
  F
  Fipronil
  Fludarabine phosphate
  Flumazenil
  Fluvastatin sodium
  G
  Gefitinib
  Gemcitabine HCl
  Gestodene
  Gestrinone
  Glimepiride
  Granisetron HCl
  H
  10-hydroxycamptothecin
  I
  Ibandronate sodium
  Ibutilide fumarate
  Imatinib mesylate
  Imipenem + Cilastatin sodium 
  Irbesartan 
  Irinotecan HCl 
  L
  Latanoprost
  Lenalidomide
  Letrozole
  Levetiracetam
  Levofloxacin 
  Levonorgestrel 
  Linezolid
  Lymecycline
  Lynoestrenol 
  M
  Maraviroc
  Melengestrol acetate
  Memantine HCl   
  Meropenem  
  Mestranol
  Methazolamide
  Mifepristone 
  Midazolam
  Miglitol 
  Mitoxantrone HCl
  Mizolastine HCl 
  Mofegiline HCl
  Mosapride citrate
  Moxidectin
  Mupirocin
  N
  N(2)-L-alanyl-L-glutamine
  Nandrolone phenylpropionate
  Nabumetone
  Natamycin
  Nebivolol
  Nedaplatin
  Nilutamide
  Norelgestromin 
  Norgestimate
  O
  Olanzapine
  Orlistat 
  Oxaliplatin 
  P
  Paclitaxel
  Palonosetron
  Pamidronate disodium
  Pemetrexed disodium
  Pemirolast potassium
  Polymyxin B sulfate
  Pramipexole 2HCl 
  Pranlukast hydrate
  R
  Racecadotril
  Rilmenidine
  Ramosetron
  Ranolazine
  Rapamycin (Sirolimus) 
  Rebamipide 
  Retigabine
  Rifaximine
  Rilmenidine  
  Riluzole 
  Risedronate sodium
  Rizatriptan benzoate
  Ropinirole
  Ropivacaine HCL
  S
  Sirolimus (Rapamycin) 
  Sorafenib tosylate
  Sunitinib malate
  T
  Tacrolimus (FK506) 
  Tamsulosin HCl 
  Tazobactam+Piperacillin 
  Teicoplanin
  Telmisartan 
  Temozolomide 
  Terazosin HCl
  Tibolone
  Tigecycline
  Topotecan HCl
  Travoprost
  Trenbolone Acetate
  Trimegestone
  Tropisetron HCL
  V
  Valsartan 
  Valrubicin 
  Vancomycin HCl
  Vecuronium bromide
  Venlafaxine HCl   
  Vinorelbine tartrate
  Voglibose
  Voriconazole
  Z
  Zanamivir
  Zoledronic acid
  Zolmitriptan
  Zonisamide

 

 

 

 

 

 

 

 

 

 

 
Haorui supplies Amifostine API (Active Pharmaceutical Ingredient) to pharmaceutical industry.  Haorui's Amifostine API is produced by FDA approved cGMP facilities, we supply Amifostine API from small R&D to large commercial quantity. For product and supply details please contact us.
Amifostine Clinical Trials 1

Amifostine Clinical Trials 1       Amifostine Clinical Trials 2
Amifostine Patents 1               Amifostine Patents 2                 Amifostine Patents 3
Amifostine Patents 4               Amifostine Patents 5
1   Completed   Toxicities Associated With Subcutaneous Administration of Ethyol (Amifostine) for the Prevention of Radiation-Induced Toxicities
Conditions:   Head and Neck Cancer;   Lung Cancer
Intervention:   Drug: Ethyol (Amifostine)
 
2   Recruiting   A Study of Amifostine (Ethyol) in Patients With Colorectal Cancer
Condition:   Colorectal Cancer
Intervention:   Drug: Amifostine
 
3   Recruiting   Amifostine With IMRT for Submandibular and Sublingual Salivary Sparing During Head and Neck Cancer Treatment
Condition:   Head and Neck Cancer
Interventions:   Drug: Amifostine;   Procedure: Intensity- Modulated Radiation Therapy
 
4   Active, not recruiting   Amifostine for Head and Neck Irradiation in Lymphoma
Conditions:   Lymphoma;   Hodgkin's Disease;   Non-Hodgkin's Lymphoma
Interventions:   Drug: Amifostine;   Radiation: Radiation Therapy
 
5   Active, not recruiting   Study Evaluating the Addition of Amifostine (Ethyol®) to Idarubicin and Cytosine Arabinoside in Older Patients With Acute Myeloid Leukemia
Conditions:   Leukemia;   Acute Myeloid Leukemia
Intervention:   Drug: Ethyol
 
6   Completed   Subcutaneous Amifostine Safety Study
Conditions:   Head and Neck Cancer;   Lung Cancer;   Lymphoma
Intervention:   Drug: Amifostine administered subcutaneously
 
7   Completed   EVALUATION OF AMIFOSTINE FOR MUCOSAL AND HEMOPOETIC PROTECTION AND CARBOPLATIN, TAXOL, RADIOTHERAPY IN THE MANAGEMENT OF PATIENTS WITH HEAD AND NECK CANCER.
Condition:   Head and Neck Cancer.
Interventions:   Drug: Amifostine;   Drug: Carboplatin;   Drug: Taxol;   Device: Radiotherapy
 
8   Recruiting   Amifostine Study
Condition:   Cancer
Intervention:   Procedure: Blood and salivary sampling of amifostine
 
9   Recruiting   Extrapleural Pneumonectomy, IHOC Cisplatin and Gemcitabine With Amifostine and Sodium Thiosulfate Cytoprotection for Resectable Malignant Pleural Mesothelioma
Condition:   Malignant Pleural Mesothelioma
Interventions:   Procedure: Extrapleural pneumonectomy (EPP);   Drug: cisplatin;   Drug: gemcitabine;   Drug: amifostine;   Drug: sodium thiosulfate
 
10   Active, not recruiting   Radiation Therapy, Combination Chemotherapy, and Amifostine in Treating Patients With Head and Neck Cancer
Conditions:   Carcinoma of Unknown Primary;   Head and Neck Cancer;   Quality of Life
Interventions:   Drug: amifostine trihydrate;   Drug: cisplatin;   Drug: fluorouracil;   Drug: paclitaxel;   Procedure: chemoprotection;   Procedure: chemotherapy;   Procedure: quality-of-life assessment;   Procedure: radiation therapy
 
11   Completed   Subcutaneous Amifostine (Ethyol®) in the Prevention of Radiochemotherapy-Induced Esophagitis and Pneumonitis in Patients With Unresectable Non-Small Cell Lung Cancer
Conditions:   Esophagitis;   Pneumonitis;   Non-Small Cell Lung Carcinoma
Intervention:   Drug: Amifostine
 
12   Completed   Azacitidine Plus Amifostine in Treating Patients With Myelodysplastic Syndrome
Condition:   Myelodysplastic Syndromes
Interventions:   Drug: amifostine trihydrate;   Drug: azacitidine;   Procedure: chemoprotection;   Procedure: chemotherapy
 
13   Recruiting   Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II or Stage III Multiple Myeloma
Conditions:   Drug Toxicity;   Multiple Myeloma and Plasma Cell Neoplasm
Interventions:   Drug: amifostine trihydrate;   Drug: clarithromycin;   Drug: dexamethasone;   Drug: melphalan;   Drug: thalidomide;   Procedure: antiangiogenesis therapy;   Procedure: bone marrow ablation with stem cell support;   Procedure: chemoprotection;   Procedure: chemotherapy;   Procedure: high-dose chemotherapy;   Procedure: management of therapy complications;   Procedure: non-specific immune-modulator therapy;   Procedure: peripheral blood stem cell transplantation
 
14   Active, not recruiting   Amifostine in Treating Patients With Advanced Myelodysplastic Syndrome
Condition:   Myelodysplastic Syndromes
Interventions:   Drug: amifostine trihydrate;   Procedure: chemotherapy
 
15   Active, not recruiting   Amifostine Plus Topotecan in Treating Patients With Myelodysplastic Syndrome
Conditions:   Leukemia;   Myelodysplastic Syndromes
Interventions:   Drug: amifostine trihydrate;   Drug: topotecan hydrochloride;   Procedure: chemoprotection;   Procedure: chemotherapy
 
16   Completed   Amifostine in Treating Patients With Cancer Who Have Neurological Changes Caused by Chemotherapy
Conditions:   Drug Toxicity;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Drug: amifostine trihydrate;   Procedure: chemoprotection
 
17   Active, not recruiting   Chemotherapy and Amifostine in Treating Patients With Recurrent or Refractory Solid Tumors
Conditions:   Drug Toxicity;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Drug: amifostine trihydrate;   Drug: cisplatin;   Drug: gemcitabine hydrochloride;   Procedure: chemoprotection;   Procedure: chemotherapy
 
18   Completed   Combination Chemotherapy With or Without Amifostine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Disease Undergoing Stem Cell Transplantation
Condition:   Lymphoma
Interventions:   Drug: amifostine trihydrate;   Drug: cisplatin;   Drug: cytarabine;   Drug: dexamethasone;   Procedure: chemoprotection;   Procedure: chemotherapy;   Procedure: hematologic toxicity attenuation;   Procedure: peripheral blood stem cell transplantation
 
19   Active, not recruiting   Amifostine in Treating Peripheral Neuropathy in Patients Who Have Received Chemotherapy for Cancer
Conditions:   Gestational Trophoblastic Tumor;   Neurotoxicity;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Drug: amifostine trihydrate;   Procedure: neurotoxicity attenuation
 
20   Active, not recruiting   Amifostine in Treating Patients With Stage II or Stage III Non-Small Cell Lung Cancer
Conditions:   Drug Toxicity;   Lung Cancer;   Oral Complications of Cancer and Cancer Therapy;   Quality of Life;   Radiation Toxicity
Interventions:   Drug: amifostine trihydrate;   Drug: carboplatin;   Drug: filgrastim;   Drug: paclitaxel;   Procedure: chemoprotection;   Procedure: chemotherapy;   Procedure: colony-stimulating factor therapy;   Procedure: quality-of-life assessment;   Procedure: radiation therapy;   Procedure: radioprotection
 
21   Active, not recruiting   Amifostine in Treating Patients With Myelodysplastic Syndrome
Condition:   Myelodysplastic Syndromes
Interventions:   Drug: amifostine trihydrate;   Procedure: chemoprotection
 
22   Active, not recruiting   Chemotherapy and Radiation Therapy With or Without Amifostine in Treating Patients With Stage III or Stage IV Head and Neck Cancer
Conditions:   Chemotherapeutic Agent Toxicity;   Dysphagia;   Head and Neck Cancer;   Mucositis;   Radiation Toxicity;   Xerostomia
Interventions:   Drug: amifostine trihydrate;   Drug: carboplatin;   Drug: paclitaxel;   Procedure: chemoprotection;   Procedure: chemotherapy;   Procedure: cytogenetic analysis;   Procedure: diagnostic procedure;   Procedure: exercise intervention;   Procedure: fatigue assessment and management;   Procedure: intensity-modulated radiation therapy;   Procedure: laboratory biomarker analysis;   Procedure: liquid chromatography;   Procedure: management of therapy complications;   Procedure: mass spectrometry;   Procedure: nutritional support;   Procedure: proteomic profiling;   Procedure: quality-of-life assessment;   Procedure: radioprotection;   Procedure: therapeutic dietary intervention
 
23   Active, not recruiting   Amifostine in Protecting the Rectum in Patients Undergoing Radiation Therapy for Prostate Cancer
Conditions:   Prostate Cancer;   Radiation Toxicity
Interventions:   Drug: amifostine trihydrate;   Procedure: radiation therapy;   Procedure: radioprotection
 
24   Active, not recruiting   Amifostine in Treating Patients With Ovarian Epithelial Cancer Who Are Receiving Chemotherapy
Conditions:   Ovarian Cancer;   Quality of Life
Interventions:   Drug: amifostine trihydrate;   Procedure: chemoprotection;   Procedure: neurotoxicity attenuation;   Procedure: quality-of-life assessment
 
25   Completed   Amifostine in Treating Young Patients With Newly Diagnosed De Novo Myelodysplastic Syndromes
Conditions:   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions:   Drug: amifostine trihydrate;   Procedure: chemotherapy
 
26   Completed   Amifostine in Treating Peripheral Neuropathy Caused by Paclitaxel in Patients With Solid Tumors
Conditions:   Breast Cancer;   Lung Cancer;   Neurotoxicity;   Ovarian Cancer;   Prostate Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Drug: amifostine trihydrate;   Procedure: management of therapy complications;   Procedure: neurotoxicity attenuation
 
27   Active, not recruiting   Amifostine With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome
Conditions:   Anemia;   Myelodysplastic Syndromes
Interventions:   Drug: amifostine trihydrate;   Drug: epoetin alfa;   Procedure: colony-stimulating factor therapy;   Procedure: hematologic toxicity attenuation
 
28   Active, not recruiting   Chemotherapy Given With Amifostine and Filgrastim in Treating Patients With Recurrent or Metastatic Cancer
Conditions:   Leukemia;   Lymphoma;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Drug: amifostine trihydrate;   Drug: carboplatin;   Drug: filgrastim;   Drug: paclitaxel;   Procedure: chemotherapy;   Procedure: colony-stimulating factor therapy;   Procedure: hematologic toxicity attenuation;   Procedure: neurotoxicity attenuation
 
29   Completed   Amifostine and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Conditions:   Drug Toxicity;   Leukemia
Interventions:   Drug: amifostine trihydrate;   Drug: cytarabine;   Drug: idarubicin;   Procedure: cardiotoxicity attenuation;   Procedure: chemotherapy;   Procedure: neurotoxicity attenuation
 
30   Active, not recruiting   Combination Chemotherapy Plus Amifostine in Treating Patients With Metastatic or Unresectable Cancer
Conditions:   Bladder Cancer;   Brain and Central Nervous System Tumors;   Carcinoma of Unknown Primary;   Extragonadal Germ Cell Tumor;   Head and Neck Cancer;   Kidney Cancer;   Lung Cancer;   Ovarian Cancer;   Sarcoma;   Testicular Germ Cell Tumor;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Drug: amifostine trihydrate;   Drug: carboplatin;   Drug: etoposide;   Drug: filgrastim;   Drug: ifosfamide;   Procedure: chemoprotection;   Procedure: chemotherapy;   Procedure: colony-stimulating factor therapy;   Procedure: peripheral blood stem cell transplantation
 
31   Completed   Amifostine in Treating Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, or Endometrial Cancer
Conditions:   Cervical Cancer;   Endometrial Cancer;   Fallopian Tube Cancer;   Neurotoxicity;   Ovarian Cancer;   Peritoneal Cavity Cancer;   Sarcoma
Interventions:   Drug: amifostine trihydrate;   Drug: cisplatin;   Drug: paclitaxel;   Procedure: chemotherapy;   Procedure: management of therapy complications;   Procedure: neurotoxicity attenuation
 
32   Active, not recruiting   Amifostine Plus Chemotherapy and Radiation Therapy in Treating Patients With Advanced, Unresectable Head and Neck Cancer
Conditions:   Drug Toxicity;   Head and Neck Cancer;   Radiation Toxicity
Interventions:   Drug: amifostine trihydrate;   Drug: cisplatin;   Drug: paclitaxel;   Procedure: chemoprotection;   Procedure: chemotherapy;   Procedure: radiation therapy;   Procedure: radioprotection
 
33   Active, not recruiting   Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer
Conditions:   Chronic Myeloproliferative Disorders;   Drug Toxicity;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Drug: amifostine trihydrate;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: sargramostim;   Procedure: chemoprotection;   Procedure: chemotherapy;   Procedure: colony-stimulating factor therapy
 
34   Active, not recruiting   Amifostine Followed by High Dose Chemotherapy in Treating Patients With Hematologic Cancer or Solid Tumors
Conditions:   Breast Cancer;   Drug Toxicity;   Lung Cancer;   Lymphoma;   Ovarian Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Drug: amifostine trihydrate;   Drug: cisplatin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: sargramostim;   Procedure: chemoprotection;   Procedure: chemotherapy;   Procedure: colony-stimulating factor therapy
 
35   Active, not recruiting   Amifostine to Prevent Side Effects in Patients Who Are Receiving Chemotherapy and Radiation Therapy for Limited-Stage Small Cell Lung Cancer
Conditions:   Drug Toxicity;   Lung Cancer;   Radiation Toxicity
Interventions:   Drug: amifostine trihydrate;   Drug: cisplatin;   Drug: etoposide;   Procedure: chemoprotection;   Procedure: chemotherapy;   Procedure: radiation therapy;   Procedure: radioprotection
 
36   Active, not recruiting   Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation
Conditions:   Drug Toxicity;   Multiple Myeloma and Plasma Cell Neoplasm
Interventions:   Drug: amifostine trihydrate;   Drug: filgrastim;   Drug: melphalan;   Procedure: bone marrow ablation with stem cell support;   Procedure: chemoprotection;   Procedure: colony-stimulating factor therapy;   Procedure: high-dose chemotherapy;   Procedure: peripheral blood stem cell transplantation
 
37   Active, not recruiting   Paclitaxel Plus Chemoprotection With Amifostine in Treating Patients With Recurrent or Refractory Solid Tumors
Condition:   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Drug: amifostine trihydrate;   Drug: paclitaxel;   Procedure: chemoprotection;   Procedure: chemotherapy
 
38   Completed   Amifostine to Treat Side Effects of Treatment in Patients Receiving Radiation Therapy and Cisplatin for Advanced Head and Neck Cancer
Conditions:   Drug Toxicity;   Head and Neck Cancer;   Oral Complications of Cancer and Cancer Therapy;   Radiation Toxicity
Interventions:   Drug: amifostine trihydrate;   Drug: cisplatin;   Procedure: chemoprotection;   Procedure: chemotherapy;   Procedure: management of therapy complications;   Procedure: radiation therapy;   Procedure: radioprotection
 
39   Active, not recruiting   Gemcitabine, Cisplatin, and Amifostine Following Surgery in Treating Patients With Locally Advanced Bladder Cancer
Conditions:   Bladder Cancer;   Drug Toxicity
Interventions:   Drug: amifostine trihydrate;   Drug: cisplatin;   Drug: gemcitabine hydrochloride;   Procedure: adjuvant therapy;   Procedure: chemoprotection;   Procedure: chemotherapy
 
40   Active, not recruiting   Amifostine to Protect From the Side Effects of Peripheral Stem Cell Transplantation in Treating Patients With High-Risk or Relapsed Solid Tumors
Conditions:   Brain and Central Nervous System Tumors;   Childhood Germ Cell Tumor;   Chordoma;   Drug Toxicity;   Extragonadal Germ Cell Tumor;   Kidney Cancer;   Liver Cancer;   Neuroblastoma;   Ovarian Cancer;   Retinoblastoma;   Sarcoma;   Testicular Germ Cell Tumor
Interventions:   Drug: amifostine trihydrate;   Drug: busulfan;   Drug: filgrastim;   Drug: melphalan;   Drug: thiotepa;   Procedure: chemoprotection;   Procedure: chemotherapy;   Procedure: colony-stimulating factor therapy;   Procedure: peripheral blood stem cell transplantation
 
41   Active, not recruiting   Docetaxel, Cisplatin, and Amifostine in Treating Patients With Advanced Non-Small Cell Lung Cancer
Conditions:   Drug Toxicity;   Lung Cancer
Interventions:   Drug: amifostine trihydrate;   Drug: cisplatin;   Drug: docetaxel;   Procedure: chemoprotection;   Procedure: chemotherapy
 
42   Active, not recruiting   Combination Chemotherapy Plus Amifostine in Treating Children With Malignant Germ Cell Tumors
Conditions:   Childhood Germ Cell Tumor;   Drug Toxicity;   Extragonadal Germ Cell Tumor;   Ovarian Cancer
Interventions:   Drug: amifostine trihydrate;   Drug: bleomycin;   Drug: cisplatin;   Drug: etoposide;   Procedure: chemoprotection;   Procedure: chemotherapy;   Procedure: conventional surgery
 
43   Active, not recruiting   Radiation Therapy Plus Amifostine in Treating Patients With Primary Prostate Cancer
Conditions:   Prostate Cancer;   Radiation Toxicity
Interventions:   Drug: amifostine trihydrate;   Procedure: radiation therapy;   Procedure: radioprotection
 
44   Active, not recruiting   Chemotherapy Plus Radiation Therapy With or Without Amifostine in Treating Patients With Locally Advanced Cancer of the Nasopharynx
Conditions:   Drug Toxicity;   Head and Neck Cancer;   Oral Complications of Cancer and Cancer Therapy;   Radiation Toxicity
Interventions:   Drug: amifostine trihydrate;   Drug: carboplatin;   Drug: cisplatin;   Drug: paclitaxel;   Procedure: chemoprotection;   Procedure: chemotherapy;   Procedure: radiation therapy;   Procedure: radioprotection
 
45   Active, not recruiting   Combination Chemotherapy, Amifostine, and Peripheral Stem Cell Transplantation in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer
Condition:   Breast Cancer
Interventions:   Drug: amifostine trihydrate;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: filgrastim;   Drug: paclitaxel;   Procedure: chemoprotection;   Procedure: chemotherapy;   Procedure: peripheral blood stem cell transplantation
 
46   Completed   Chemotherapy, Amifostine, and Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer
Conditions:   Drug Toxicity;   Lung Cancer
Interventions:   Drug: amifostine trihydrate;   Drug: carboplatin;   Drug: paclitaxel;   Procedure: chemoprotection;   Procedure: chemotherapy;   Procedure: radiation therapy
 
47   Active, not recruiting   Radiation Therapy and Cisplatin With or Without Amifostine in Treating Patients With Stage IIIB or Stage IVA Cancer of the Cervix
Conditions:   Cervical Cancer;   Radiation Toxicity
Interventions:   Drug: amifostine trihydrate;   Drug: cisplatin;   Procedure: brachytherapy;   Procedure: chemotherapy;   Procedure: radiation therapy;   Procedure: radioprotection
 
48   Recruiting   Radiation Therapy, Carboplatin, and Paclitaxel With or Without Amifostine in Treating Patients With Stage II, Stage III, or Stage IV Head and Neck Cancer
Conditions:   Drug Toxicity;   Head and Neck Cancer;   Oral Complications of Chemotherapy and Head/Neck Radiation;   Radiation Toxicity
Interventions:   Drug: amifostine trihydrate;   Drug: carboplatin;   Drug: paclitaxel;   Procedure: chemoprotection;   Procedure: chemotherapy;   Procedure: management of therapy complications;   Procedure: radiation therapy;   Procedure: radioprotection
 
49   Active, not recruiting   Amifostine, Chemotherapy, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer
Conditions:   Drug Toxicity;   Lung Cancer;   Radiation Toxicity
Interventions:   Drug: amifostine trihydrate;   Drug: cisplatin;   Drug: etoposide;   Procedure: chemoprotection;   Procedure: chemotherapy;   Procedure: radiation therapy;   Procedure: radioprotection
 
50   Active, not recruiting   Amifostine and High-Dose Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Chronic Myelogenous Leukemia
Conditions:   Drug Toxicity;   Leukemia;   Myelodysplastic Syndromes;   Neutropenia
Interventions:   Drug: amifostine trihydrate;   Drug: cytarabine;   Drug: mitoxantrone hydrochloride;   Procedure: chemotherapy;   Procedure: hematologic toxicity attenuation

 
 

Haorui - Your Partner to Pharmaceutical Success - Copy Right Reserved